Larotinib
Small moleculeexperimental
Clinical trial activity
4 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Aug 18, 2017 (NCT03888092)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06145308 | Phase 2 | Dec 1, 2023 | Peking University |
| NCT05059743 | Phase 1 | Dec 30, 2021 | Soochow University, Sunshine Lake Pharma Co., Ltd. |
| NCT04131192 | Phase 1 | Oct 30, 2019 | Nanjing Medical University, Shandong University, Sunshine Lake Pharma Co., Ltd. |
| NCT03888092 | Phase 1/Phase 2 (Phase 2) | Aug 18, 2017 | People's Liberation Army of China, Sunshine Lake Pharma Co., Ltd. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sunshine Lake Pharma Co., Ltd. | For profit | 3 | 3 | 2 | 2017 |
| Nanjing Medical University | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Peking University | Academic/Hospital | 1 | 0 | 1 | 2023 |
| People's Liberation Army of China | Government | 1 | 0 | 1 | 2017 |
| Shandong University | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Soochow University | Academic/Hospital | 1 | 0 | 1 | 2021 |
6 organizations
Page 1 / 1